Exciting news! Clinical research on stereotactic percutaneous live tumor ablation using Surgnova’s Dophi™M150E system conducted by University Medical Center Regensburg is published on Cancers.

The result shows primary technique efficacy (PTE) is 97.4%, verifying the outstanding effectiveness and safety and reliability in achieving reproducible and predictable ablation.

Thank all the researchers contributed to this significant clinical study, especially the support of Dr. Lukas Luerken and Dr. Ingo Einspieler, Head of the Center for Radiological Interventional Oncology in Universitätsklinikum Regensburg! Hope our Dophi™M150E system will benefit more patients worldwide!

Click here for more details on the research. https://lnkd.in/gJ7pxSFB